[공지] Alligator Bioscience사 면역치료용 항체 7000억 규모 라이센싱아웃 계약 체결
앱클론과 공동으로 혁신항체신약을 개발하고 있는 스웨덴 생명공학기업 Alligator Bioscience사가 현재 개발중인 CD40을 타겟으로 한 암면역치료용 항체를 세계적인 글로벌 제약 기업 Janssen Biotech사에 7,000억 규모의 기술이전계약을 체결하였습니다. 상세 내용은 아래와 같습니다. [보도 내용 전문] Alligator Bioscience Announces Collaboration with Johnson & Johnson Innovation for the CD40 Agonistic Immuno-Oncology Antibody ADC-101312 August 2015 Alligator Bioscience AB, a privately held Swedish biotech company developing immuno-oncologyantibodies for directed immunotherapy of cancer, today announced that it has entered into a definitiveagreement with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies ofJohnson & Johnson.Under the agreement, Janssen, will be granted an exclusive, worldwide license to Alligator’s clinicalcandidate ADC-1013. The collaboration was facilitated by the Johnson & Johnson Innovation Center inLondon. Currently in Phase I clinical trials, ADC-1013 is an agonistic fully human monoclonal antibodytargeting CD40, an immuno-stimulatory receptor found on antigen-presenting cells such as dendriticcells. Stimulation of CD40 on dendritic cells initiates a process leading to a dramatic increase in Teffector cells attacking the tumor. In addition, a tumor-specific memory is established leading to longterm immunity to the cancer.Alligator Bioscience will receive an up-front payment plus additional contingent payments uponreaching certain pre-determined development, regulatory and commercial milestones up to a potentialtotal of US$700 million. Alligator is also eligible to receive tiered royalties on worldwide net sales uponsuccessful launch and commercialization. In a simultaneous transaction Johnson & Johnson Innovation -JJDC, Inc. will subscribe for new shares of Alligator common stock.The closing of the transaction is subject to clearance under the Hart-Scott-Rodino AntitrustImprovements Act.Janssen will be responsible for developing ADC-1013 and will assume responsibility for the clinicalstudies once the current Phase I dose escalation study is complete. Janssen will have exclusive rights todevelop and commercialize ADC-1013 initially targeting a number of solid tumors and hematologicalcancers and will assume responsibility for all additional research, development, manufacturing,regulatory and commercialization activities.“This is a key milestone for Alligator Bioscience” said Peter Benson, Chairman of the Board of Directors.“ADC-1013, based on a promising and positive pre-clinical data package, is now in Phase I clinical trials.We are very pleased to welcome this collaboration with a leading, global oncology company and lookforward to working together to ensure ADC-1013 will be benefitting patients as soon as possible.” About AlligatorAlligator Bioscience discovers and develops innovative antibody based immunotherapies for thetreatment of cancer. Alligator Drug Discovery and Development span early research phases with leadidentification up to proof of concept phase I/II clinical studies in cancer patients. In the discovery ofnovel antibody based drugs, Alligator uses its proprietary technology platforms FIND® and ALLIGATORGOLD®. FIND® (Fragment INduced Diversity) is an antibody optimization technology based on singlestranded DNA allowing generation of antibodies with significant clinical benefits. ALLIGATOR-GOLD® is a synthetic svFv library containing several billion distinct fully human antibodies. Alligator Bioscience ABwas founded in 2001 and is a privately held company with around 200 shareholders, located at MediconVillage in Lund, Sweden.Alligators largest shareholders are the Copenhagen-based venture fund Sunstone Capital and DUBA AB,a fully-owned subsidiary of Investor AB, as well as some private individual investors.Alligator Bioscience engaged Colpman Consulting Ltd as lead advisor in the partnering process. Wigginand Dana LLP and Setterwalls Advokatbyrå AB acted as legal advisors to the transaction. EY acted as taxadvisors.